Mutual of America Capital Management LLC Sells 2,802 Shares of Illumina, Inc. $ILMN

Mutual of America Capital Management LLC reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 78,723 shares of the life sciences company’s stock after selling 2,802 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Illumina were worth $7,511,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ILMN. Vanguard Group Inc. boosted its holdings in shares of Illumina by 3.5% in the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company’s stock worth $1,298,928,000 after buying an additional 558,243 shares during the last quarter. WCM Investment Management LLC lifted its stake in Illumina by 5.9% during the second quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock worth $419,585,000 after purchasing an additional 247,460 shares during the last quarter. Corvex Management LP boosted its stake in shares of Illumina by 125.2% in the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock valued at $303,841,000 after purchasing an additional 2,129,449 shares in the last quarter. Brown Advisory Inc. grew its position in Illumina by 52.1% during the 1st quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company’s stock worth $230,818,000 after acquiring an additional 996,589 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Illumina by 361.7% in the first quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company’s stock valued at $165,484,000 after acquiring an additional 1,662,093 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Trading Up 4.2%

Shares of ILMN stock opened at $99.50 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The company has a 50-day moving average of $98.22 and a two-hundred day moving average of $91.01. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The firm has a market cap of $15.29 billion, a PE ratio of 12.59, a price-to-earnings-growth ratio of 2.31 and a beta of 1.40.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the firm posted $0.36 earnings per share. The company’s revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ILMN. Citigroup cut shares of Illumina from a “hold” rating to a “strong sell” rating and dropped their price target for the stock from $85.00 to $80.00 in a research note on Wednesday, July 9th. Stephens set a $110.00 target price on shares of Illumina and gave the company an “overweight” rating in a research report on Monday, August 4th. Evercore ISI decreased their price target on Illumina from $135.00 to $132.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Barclays upped their target price on Illumina from $90.00 to $95.00 and gave the stock an “underweight” rating in a report on Thursday, October 2nd. Finally, Royal Bank Of Canada set a $124.00 target price on Illumina in a research note on Tuesday, September 2nd. Five research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $115.25.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.